本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Mesoblast Limited

14.63
-0.3900-2.60%
成交量:6.21萬
成交額:91.02萬
市值:18.97億
市盈率:-32.95
高:14.80
開:14.80
低:14.59
收:15.02
52周最高:21.50
52周最低:13.05
股本:1.30億
流通股本:8,411.79萬
量比:1.41
換手率:0.07%
股息:- -
股息率:- -
每股收益(TTM):-0.4440
每股收益(LYR):-0.4441
淨資產收益率:-9.86%
總資產收益率:-4.11%
市淨率:3.34
市盈率(LYR):-32.95

資料載入中...

公司資料

公司名字:
Mesoblast Limited
交易所:
NASDAQ
成立時間:
2004
員工人數:
108
公司地址:
55 Collins Street,Level 38,Melbourne,Victoria,Australia
郵編:
3000
傳真:
61 3 9639 6030
簡介:
Mesoblast Limited於2004年6月8日在澳大利亞成立。該公司在開發同種異體細胞藥物方面處於世界領先地位。該公司利用其專有的間充質譜系細胞治療技術平台建立了廣泛的商業產品和後期產品候選產品組合。

董事

名稱
職位
Philip Facchina
Chairman of the Board and Non-Executive Director
Silviu Itescu
Chief Executive Officer,Executive Director and Managing Director
William Burns
Non-Executive Director and Vice Chairman
Eric Rose
Chief Medical Officer and Executive Director
Gregory George
Non-Executive Director
Jane Bell
Non-Executive Director
Lyn Cobley
Non-Executive Director
Philip Krause
Non-Executive Director

股東

名稱
職位
Silviu Itescu
Chief Executive Officer,Executive Director and Managing Director
James O'Brien
Chief Financial Officer
Eric Rose
Chief Medical Officer and Executive Director
Fiona See
Head of Translational Research
Geraldine Storton
Head of Regulatory Affairs and Quality Management
Justin Horst
Head of Manufacturing
Marcelo Santoro
Chief Commercial Officer
Michael Schuster
Pharma Partnering
Niva Sivakumar
Associate General Counsel and Company Secretary
Paul Hughes
Company Secretary